Wang S F, Yin Z, Yin J J, Zhang W, Dong C G
Department of Pathology, Linyi People's Hospital of Shandong Province, Linyi, China.
Department of Ophthalmology, Zoucheng People's Hospital of Shandong Province, Zoucheng, China.
Genet Mol Res. 2016 May 23;15(2):gmr7855. doi: 10.4238/gmr.15027855.
The aim of this meta-analysis was to investigate the overall diagnostic and prognostic values of CTHRC1 expression in human cancer development. Based on the inclusion and exclusion criteria, 8 cohort studies were included in the meta-analysis. The data were extracted, and analyses were performed using a random-effects model. Summary odds ratios (ORs) and effect sizes (ESs) with 95% confidence intervals (CIs) were calculated to assess the strength of the associations. A total of 1065 cancer patients from the 8 studies were included in the meta-analysis. The results revealed a positive correlation of CTHRC1 protein expression in tumors with tumor-node-metastasis (TNM) stage and with lymph node (LN) metastasis (TNM: OR = 2.98, 95%CI = 1.48-6.00, P = 0.002; LN: OR = 4.26, 95%CI = 1.88-9.67, P = 0.001). CTHRC1 expression was higher in tumors with sizes ≥5 cm than in tumors with sizes <5 cm (OR = 2.39, 95%CI = 1.12-5.09, P = 0.024). Patients with higher CTHRC1 expression had decreased overall survival (OS) (ES = 1.78, 95%CI = 1.23-2.33, P < 0.001) and poorer disease-free survival (DFS) (ES = 1.71, 95%CI = 1.11-2.31, P < 0.001). Disease-stratified analyses yielded significantly different estimates of CTHRC1 levels in the majority of the subgroups (all P < 0.05). In conclusion, increased CTHRC1 expression is associated with advanced TNM stage, increased LN metastasis and tumor size, and decreased OS and DFS, indicating that CTHRC1 may be a biomarker for prognosis of cancer patients.
本荟萃分析的目的是研究CTHRC1表达在人类癌症发生发展中的总体诊断和预后价值。基于纳入和排除标准，8项队列研究被纳入该荟萃分析。提取数据，并使用随机效应模型进行分析。计算汇总比值比（OR）和效应大小（ES）以及95%置信区间（CI），以评估关联强度。这8项研究中的1065例癌症患者被纳入荟萃分析。结果显示，肿瘤中CTHRC1蛋白表达与肿瘤-淋巴结-转移（TNM）分期以及淋巴结（LN）转移呈正相关（TNM：OR = 2.98，95%CI = 1.48 - 6.00，P = 0.002；LN：OR = 4.26，95%CI = 1.88 - 9.67，P = 0.001）。大小≥5 cm的肿瘤中CTHRC1表达高于大小<5 cm的肿瘤（OR = 2.39，95%CI = 1.12 - 5.09，P = 0.024）。CTHRC1表达较高的患者总生存期（OS）降低（ES = 1.78，95%CI = 1.23 - 2.33，P < 0.001），无病生存期（DFS）较差（ES = 1.71，95%CI = 1.11 - 2.31，P < 0.001）。疾病分层分析在大多数亚组中得出了CTHRC1水平的显著不同估计值（所有P < 0.05）。总之，CTHRC1表达增加与晚期TNM分期、LN转移增加和肿瘤大小增加以及OS和DFS降低相关，表明CTHRC1可能是癌症患者预后的生物标志物。
